21:27 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

GSK begins Phase II of malaria vaccine candidate

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) began a Phase II trial of intramuscular RTS,S vaccine (Mosquirix, GSK257049) to vaccinate against malaria infection. The open-label, U.S. trial will evaluate adult and pediatric formulations of the vaccine in 160 malaria-naïve...
01:37 , Apr 6, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Blood levels of immune cell markers and antibodies could help predict protective responses to Plasmodium CSP-based malaria vaccines. A cohort of 46 healthy volunteers received one of two malaria vaccine regimens before challenge...
16:20 , Jan 12, 2017 |  BC Week In Review  |  Company News

GeneCentric, Bristol-Myers Squibb deal

Bristol-Myers Squibb and GeneCentric partnered to explore the feasibility of using GeneCentric’s Cancer Subtype Platform (CSP) to identify translational biomarkers for cancer drug Opdivo nivolumab for use in clinical trials. The pharma will provide undisclosed...
22:30 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

GAP3KO vaccine: Ph I data

An open-label, U.S. Phase I trial in 10 healthy volunteers showed that GAP3KO administered via the bite of 150-200 GAP3KO-infected mosquitoes under controlled conditions prevented malaria infection in all subjects. Specifically, all 10 subjects developed...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Oberland Capital Management LLC, Agenus deal

Agenus sold its royalty stream on sales of shingles vaccine HZ/su and malaria vaccine RTS,S ( Mosquirix) to Oberland for a $100 million note. Agenus will receive an additional $15 million note if FDA...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

RTS regulatory update

EMA’s CHMP recommended approval of Mosquirix from GlaxoSmithKline for active immunization of children ages 6 weeks to 17 months against malaria caused by Plasmodium falciparum and against hepatitis B. The malaria vaccine targeting the circumsporozoite...
01:12 , Jul 25, 2015 |  BC Extra  |  Company News

CHMP backs GSK's malaria vaccine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) received a positive opinion from EMA's CHMP for its Mosquirix malaria vaccine in children aged 6 weeks to 17 months -- moving the product a step closer to becoming the first...
08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Plasmodium sporozoite asparagine-rich protein (SLARP); P. falciparum circumsporozoite protein B9 (B9; CSP)

Infectious disease INDICATION: Malaria In vitro and mouse studies suggest a genetically attenuated parasite could be used to vaccinate against malaria. Plasmodium berghei with engineered deletions of the B9 and SLARP genes - which are required for...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

RTS regulatory update

EMA accepted for review an MAA from GlaxoSmithKline for its RTS,S malaria vaccine - moving the product closer to being the first vaccine approved to prevent malaria infection in infants and children. There are currently...
23:55 , Jul 24, 2014 |  BC Extra  |  Company News

EMA to review GSK's malaria vaccine

EMA accepted for review an MAA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for its RTS,S malaria vaccine -- moving the product closer to being the first vaccine approved to prevent malaria infection in infants and children....